Editors' Pick Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, et al. Lancet. 2012 Oct 31. PMID: 23122650. Abstract CommentRecommendBookmarkWatch
